B. Palache

发表

IMMUNOGENICITY AND TOLERABILITY OF A TRIVALENT INFLUENZA SUBUNIT VACCINE (INFLUVAC®) IN HIGH‐RISK CHILDREN AGED 6 MONTHS TO 4 YEARS

R. Kerstens, P. Daubeney, C. Taylor, 1997, The British journal of clinical practice.

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.

I. D. de Bruijn, B. Palache, Ingo Meyer, 2007, Vaccine.

Innovation for growth in mature industries: Solvay's influenza business

W. Vanhaverbeke, B. Palache, J. Crijns, 2009 .

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Y. Zoellner, B. Gradl, B. Palache, 2006, Vaccine.

Antiviral and adjuvant activity of immunomodulator adamantylamide dipeptide.

K. Mašek, B. Palache, K. Masihi, 1992, Advances in experimental medicine and biology.

Global influenza vaccine distribution survey demonstrates urgency of implementation of objective 3 of WHO influenza strategy 2019-2030.

B. Palache, P. Barbosa, 2020 .

New vaccine approaches for seasonal and pandemic influenza.

B. Palache, 2008, Vaccine.

The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems.

M. Van Ranst, Y. Zöllner, B. Palache, 2023, Expert Review of Vaccines.

Global seasonal influenza disease and vaccination: a paradox with substantial public health implications

B. Palache, 2018 .

Progress with human H5N1 vaccines: a perspective from industry

B. Palache, R. Krause, 2009, Expert review of vaccines.

Influenza vaccine supply: building long-term sustainability.

L. Hessel, B. Palache, N. Hehme, 2008, Vaccine.